Clinical trials: Antibody
Primary Immune Deficiency
Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement therapy.
- Trial name
- NCT00680446
- Testing
- Immunoglobulin G (Ig NextGen 16%)
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 41 people
- Sponsor
- CSL Limited
SARS-Cov-2, Covid19
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.
- Trial name
- NCT04699903
- Testing
- POC SARS-Cov-2 IgG Antibody test
- Where
- 3 sites in United States
- Volunteers
- 201 people
- Sponsor
- Lumos Diagnostics
Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS)
Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging
The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy.
- Conditions
- Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, AL Amyloidosis
- Trial name
- MGUS-PET (NCT07624760)
- Testing
- ¹⁸F-florbetaben
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Healthy
Safety Study of LY3041658 in Healthy Participants
The main purpose of this study is to evaluate the safety of LY3041658 in healthy participants, including first generation Japanese. The study will also investigate how the drug is processed and affects key immune cells.
- Trial name
- NCT02148627
- Testing
- LY3041658 (SC), LY3041658 (IV)
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dengue
A Controlled Human Infection Model of Dengue
This study aims to conduct a safe human infection challenge using an attenuated serotype DEN3 dengue virus in adult volunteers. The clinical, viral and immune response characteristics of the model will be analysed to understand…
- Trial name
- DEN-CHIM-01 (NCT07412483)
- Testing
- GMP-produced rDEN3delta30 virus
- Where
- Singapore
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Recurrent Colon Cancer, Recurrent Rectal Cancer
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Radiolabeled monoclonal antibodies can find tumor cells and either kill them or carry tumor-killing substances to them without harming normal cells.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01205022
- Testing
- irinotecan hydrochloride, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Triple Negative Breast Neoplasms
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Phase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients.
- Trial name
- A-Brave (NCT02926196)
- Testing
- MSB0010718C
- Where
- 70 sites in Italy, United Kingdom
- Volunteers
- 474 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Stage IV Bladder Urothelial Carcinoma, Prostate Cancer
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody…
- Conditions
- Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
- Trial name
- NCT02717156
- Testing
- Computed Tomography, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of Southern California
Non-small- Cell Lung Cancer (NSCLC)
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-mutated unresectable or metastatic non-small-cell lung cancer (NSCLC).
- Trial name
- NCT05141786
- Testing
- MRG002
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Miracogen Inc.
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
- Trial name
- NCT01350141
- Testing
- PF-04950615 (RN316)
- Where
- 35 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Relapsed Refractory Multiple Myeloma (RRMM)
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of…
- Trial name
- NCT07831122
- Testing
- Belamaf, Cevostamab, Pomalidomide
- Where
- 7 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Canadian Myeloma Research Group
PROC, Platinum Resistant Ovarian Cancer
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.
- Conditions
- PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT07470853
- Testing
- HWK-016, MUCIN-16-targeted ADC, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 265 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Breast Neoplasms, Stomach Neoplasms
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
This is a 2-part, Phase 1 FIH study with Phase 1a designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) in subjects with metastatic cancers with a human epidermal growth factor receptor 2 (HER2)…
- Trial name
- NCT02512237
- Testing
- ARX788
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Zhejiang Medicine Co., Ltd.
EBV, Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
- Trial name
- NCT06908096
- Testing
- EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ANCA-related Vasculitis
Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients
Laboratory testing of Anti-Neutrophil Cytoplasm Antibody (ANCA) is used to confirm diagnosis of patients who have a high level of suspicion for ANCA-related vasculitis.
- Trial name
- NCT01238003
- Testing
- Interpretation of blood test results
- Where
- Israel
- Volunteers
- 380 people
- Sponsor
- Hillel Yaffe Medical Center
Metastatic Solid Tumors
SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors
This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.
- Trial name
- NCT07728942
- Testing
- SLR-108, SLX-1411
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Solve Therapeutics
HRD Cancer, SCLC
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Background: Small cell lung cancer and PARP inhibitor resistant tumors are aggressive cancers. Current treatments for people with these tumors yield little benefit. Researchers want to see if a combination of drugs can help.
- Conditions
- HRD Cancer, SCLC, Advanced Solid Tumors
- Trial name
- NCT04826341
- Testing
- Berzosertib, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Solid Tumour
ADC-induced Neurotoxicity Treated With Duloxetine
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is effective in treating peripheral neuropathy caused by antibody-drug conjugate.
- Trial name
- NCT06551051
- Testing
- duloxetine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.